当前位置:首页 - 行情中心 - 泽璟制药-U(688266) - 财务分析 - 现金流量表

泽璟制药-U

(688266)

  

流通市值:251.39亿  总市值:251.39亿
流通股本:2.65亿   总股本:2.65亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金625,943,869.14384,677,977.23193,163,300.7548,643,541.75
  收到其他与经营活动有关的现金140,197,696.5190,465,216.6423,618,133.09324,185,470.57
  经营活动现金流入小计766,141,565.65475,143,193.87216,781,433.79872,829,012.32
  购买商品、接受劳务支付的现金24,889,535.5413,814,093.576,948,762.6355,730,803.77
  支付给职工以及为职工支付的现金256,185,507.54176,226,028.998,927,141.04306,919,736.08
  支付的各项税费51,276,975.1231,750,901.9512,528,233.3651,238,477.03
  支付其他与经营活动有关的现金450,523,469.31270,372,445.53104,630,449.18420,735,450.65
  经营活动现金流出小计782,875,487.51492,163,469.95223,034,586.21834,624,467.53
  经营活动产生的现金流量净额-16,733,921.86-17,020,276.08-6,253,152.4238,204,544.79
二、投资活动产生的现金流量:
  收回投资收到的现金65,492,20017,179,2007,177,4001,202,227,200
  取得投资收益收到的现金451,333.33194,000-14,861,369.19
  投资活动现金流入小计65,943,533.3317,373,2007,177,4001,217,088,569.19
  购建固定资产、无形资产和其他长期资产支付的现金132,497,229.0679,715,800.3633,808,123.1295,690,254.8
  投资支付的现金---2,966,499,701.53
  投资活动现金流出小计132,497,229.0679,715,800.3633,808,123.123,062,189,956.33
  投资活动产生的现金流量净额-66,553,695.73-62,342,600.36-26,630,723.12-1,845,101,387.14
三、筹资活动产生的现金流量:
  吸收投资收到的现金---339,648.68
  取得借款收到的现金616,021,145.08431,521,145.08141,321,903.341,288,278,854.92
  筹资活动现金流入小计616,021,145.08431,521,145.08141,321,903.341,288,618,503.6
  偿还债务支付的现金507,070,075.83317,070,075.83162,000,0001,134,800,000
  分配股利、利润或偿付利息支付的现金19,466,662.0812,721,068.856,297,303.4124,563,574.91
  支付其他与筹资活动有关的现金90,169,404.0975,817,164.914,820,707.87180,571,344.23
  筹资活动现金流出小计616,706,142405,608,309.59173,118,011.281,339,934,919.14
  筹资活动产生的现金流量净额-684,996.9225,912,835.49-31,796,107.94-51,316,415.54
四、汇率变动对现金及现金等价物的影响-527,602.39-453,654.23-9,211.92-2,298,440.51
五、现金及现金等价物净增加额-84,500,216.9-53,903,695.18-64,689,195.4-1,860,511,698.4
  加:期初现金及现金等价物余额217,265,493.08217,265,493.08217,265,493.082,077,777,191.48
  期末现金及现金等价物余额132,765,276.18163,361,797.9152,576,297.68217,265,493.08
补充资料:
  净利润--75,569,945.5--150,298,322.91
  资产减值准备-3,358,109.26--
  固定资产和投资性房地产折旧-12,070,051.42-22,439,936.01
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-12,070,051.42-22,439,936.01
  无形资产摊销-9,399,847.16-20,824,367.21
  长期待摊费用摊销-2,869,292.11-5,727,001.74
  处置固定资产、无形资产和其他长期资产的损失--810.44--
  公允价值变动损失----3,919,137.25
  财务费用--13,409,228.02--22,550,549.39
  投资损失--800,771.56--2,939,351.7
  递延所得税--2,009,690.11--3,881,518.13
    递延所得税负债增加--2,009,690.11--3,881,518.13
  存货的减少--15,287,856.49--72,008,791.43
  经营性应收项目的减少--39,844,818.4--58,167,052.89
  经营性应付项目的增加-85,177,377.53-285,266,612.13
  其他-10,828,754.36-1,617,266.48
  不涉及现金收支的投资和筹资活动金额其他项目---70,925,241.9
  现金的期末余额-163,361,797.9-217,265,493.08
  减:现金的期初余额-217,265,493.08-2,077,777,191.48
  现金及现金等价物的净增加额--53,903,695.18--1,860,511,698.4
公告日期2025-10-312025-08-232025-04-192025-04-19
审计意见(境内)标准无保留意见
TOP↑